Mode
Text Size
Log in / Sign up

S100A8/A9 promotes tumor microenvironment remodeling and serves as a potential therapeutic target in colorectal cancerProtein levels may signal how colorectal cancer spreads and grows

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that S100A8/A9 is a potential therapeutic target for colorectal cancer but not a proven treatment.

This systematic review explores the role of S100A8/A9 in colorectal cancer (CRC) progression and its implications for therapeutic intervention. The authors synthesize evidence indicating that aberrant expression of S100A8/A9 serves as a critical regulatory factor in CRC development, specifically associated with poorer prognosis in advanced-stage cases.

The review highlights how S100A8/A9 remodels the tumor microenvironment (TME). Specifically, it amplifies inflammatory responses, establishes immunotolerant conditions, and promotes metastatic tumor phenotypes. Furthermore, it is involved in forming pre-metastatic and angiogenic niches while contributing to anti-tumor immunity suppression, tumor invasion, and metastasis.

While S100A8/A9 is identified as a potential therapeutic target through various modalities including receptor-pathway blockade and combination therapy, the review notes these are emerging strategies. Clinical trial data for these interventions were not reported in this synthesis. Practice relevance is currently limited to its identification as a biomarker and a candidate for future precision-delivery approaches.

How this fits prior evidence

This finding addresses a gap in identifying specific molecular targets within the tumor microenvironment of colorectal cancer. While prior coverage identified 14-3-3 proteins as potential but unvalidated biomarkers and highlighted the role of deep learning models for detection, this review focuses on S100A8/A9 as a driver of inflammation and metastasis. It complements existing knowledge regarding poor prognosis markers, such as high NLRP-3 expression in solid cancers.

When colorectal cancer spreads, it often creates a protective shield around itself. New research highlights a protein called S100A8/A9 that plays a major role in this process. When this protein is present in high amounts, it changes the area around the tumor to help the cancer grow and move to other parts of the body.

This protein does more than just sit there. It triggers inflammatory responses and creates conditions where the immune system cannot effectively fight the cancer. It also helps build environments that allow tumors to develop new blood vessels and spread. Because it is linked to a poorer outlook for patients with advanced stages of the disease, it is being looked at closely by researchers.

While this protein is not a treatment itself, it offers a path forward for medicine. Scientists are looking into ways to block its pathways or use other methods to target it directly. These studies focus on how we might eventually stop the cancer from creating these protective zones.

What this means for you:
The S100A8/A9 protein helps colorectal cancer grow and spread by creating a protective environment for tumors.

Common questions

What is the role of S100A8/A9 in colorectal cancer?

The S100A8/A9 protein acts as a regulator that helps colorectal cancer develop and progress. When it shows abnormal levels, it is linked to a poorer outlook for patients, especially those with advanced stages of the disease.

How does this protein affect the area around a tumor?

This protein changes the environment around the tumor by increasing inflammation and creating conditions where the immune system cannot fight the cancer. It also helps create areas that allow tumors to grow blood vessels and spread.

Can S100A8/A9 be used as a treatment?

S100A8/A9 is not a proven treatment, but it is identified as a potential target for future therapies. Researchers are exploring ways to block its pathways or use other methods to target the protein directly.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
S100A8/A9, a key member of the calcium-binding protein family, exerts multiple biological effects through its aberrant expression, and serves as an important regulatory factor in the development and progression of colorectal cancer (CRC). Its activity remodels the tumor microenvironment (TME) by amplifying inflammatory responses, establishing immunotolerant conditions, promoting metastatic tumor phenotypes, and forming pre-metastatic and angiogenic niches. These processes suppress anti-tumor immunity, enhance tumor invasion and metastasis, and are associated with poorer prognosis, particularly in advanced-stage CRC. Despite the complexity of its regulatory network, S100A8/A9 represents a valuable potential therapeutic target. This review systematically summarizes the biological properties, clinical significance, and tumor microenvironment-related mechanisms of S100A8/A9 in CRC, with emphasis on inflammation, immune regulation, invasion, metastasis, biomarker potential, and therapeutic targeting. We further discuss emerging S100A8/A9-based intervention strategies, including direct molecular targeting, receptor-pathway blockade, natural-product modulation, combination therapy, and precision-delivery approaches, aiming to clarify both the translational opportunities and limitations of S100A8/A9-directed precision management in CRC.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.